LLY vs SDGR

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Score Change Explanation: The score has been adjusted downwards from 82 to 79 primarily due to two material changes impacting near-term outlook and investor sentiment. Firstly, management announced at the Leerink Conference (March 10, 2026) an *expected revenue decline for 2026*, shifting to an ACV metric, and pushing profitability targets to 2028. This directly impacts financial trajectory and de...